The 20 Best Follicular Lymphoma Doctors near Baltimore, MD

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Elite provider by MediFind in the treatment of Follicular Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as a Distinguished provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as a Distinguished provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Advanced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Myelodysplastic Syndrome (MDS), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Aspiration.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Advanced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Chronic B-Cell Leukemia (CBCL).

Ravin Garg is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Garg is rated as an Advanced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Breast Cancer, and Thrombotic Thrombocytopenic Purpura.

Richard J. Jones, M.D., is a Professor of Oncology and Medicine, Director of the Bone Marrow Transplantation Program, and Co-Director of the Hematologic Malignancies Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Jones received his Bachelor of Science in chemistry from Bucknell University prior to completing his medical degree at the Temple University School of Medicine. He then completed his residency at Temple University Hospital, where he was appointed to serve as Chief Resident in Internal Medicine. Dr. Jones later came to Johns Hopkins to complete his Medical Oncology Fellowship, and was then recruited to the faculty. Dr. Jones’ research is aimed at better understanding the biology of normal and cancer stem cells, with the goal of translating promising findings to the clinic particularly in the area of blood and marrow transplantation (BMT). Dr. Jones' laboratory discovered one the most commonly-used stem cell markers, Aldefluor which identifies cells based on their expression of aldehyde dehydrogenase 1 (ALDH1), and have used this marker to identify and characterize normal stem cells and cancer stem cells from many hematologic malignancies. This work also led to the development of post-transplant cyclophosphamide and effective related haploidentical BMT. Cyclophosphamide is metabolized by ALDH1, which is the reason both stem cells and memory lymphocytes are resistant to the drug. Recently, Dr. Jones' laboratory found that cytochrome P450 enzymes are a major mechanism by which the bone marrow stem cell niche protects both normal and leukemia stem cells. Dr. Jones co-leads the Hematologic Malignancies and Bone Marrow Transplantation Research Program. In addition to his promising work in the laboratory, Dr. Jones is recognized as a gifted mentor. During his tenure at Hopkins, he has trained a generation of leading physician-scientists who have excelled at Johns Hopkins and across the country. Dr. Jones has also authored numerous peer-reviewed articles that have been published in such prestigious journals as Blood, Nature, the New England Journal of Medicine, Lancet, PNAS, the Annals of Internal Medicine, the Journal of Clinical Oncology, the Journal of the National Cancer Institute, the British Journal of Haematology, and Leukemia. Dr. Jones is rated as an Experienced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, and Myelodysplastic Syndrome (MDS).

Dr. Sterling is an oncologist who cares for patients with hematologic malignancies at the Johns Hopkins University School of Medicine. He is an active clinician with expertise in lymphoma and bone marrow transplantation and serves as the Director of the Johns Hopkins Lymphoma and Myeloma Multidisciplinary Conference. Dr. Sterling earned his undergraduate degree in biomedical sciences from Auburn University and his medical degree from Johns Hopkins University. He completed his training in internal medicine and medical oncology at Johns Hopkins before being recruited to the faculty. As a clinical investigator, Dr. Sterling's research focuses on the development of new technologies, therapies, and treatment strategies for lymphoma and other conditions treated with bone marrow transplantation. Dr. Sterling is rated as an Experienced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, and Peripheral T-Cell Lymphoma.

As a physician scientist in the hematological malignancies and stem cell transplantation division with Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins, my focus is on the various aspects of cellular therapy in the treatment of hematological malignancies. My primary research focus is to develop strategies to prevent relapse of hematological malignancies following allogeneic stem cell transplantation. Additionally, I serve as the director of the adult CAR T program for hematological malignancies as we grow our CAR T program to help patients with advanced hematological malignancies. My academic interest in this space lies in studying the aspects of toxicity of CAR T cell therapy with an aim to improve long term outcomes in these patients. Among hematological malignancies, myeloproliferative disorders are my area of interest and I work to study newer drugs in early phase of development and also its treatment using allogeneic stem cell transplantation. Patient appointments: 410-955-8893. Dr. Jain is rated as an Experienced provider by MediFind in the treatment of Follicular Lymphoma. Her top areas of expertise are Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenomegaly, Bone Marrow Transplant, and Splenectomy.

Dr. Philip Imus is an oncologist in the Baltimore area, caring for patients with hematologic malignancies. Dr. Imus received his undergraduate degree (cum laude) in English from Rice University. He earned his M.D. from Columbia University College of Physicians and Surgeons. He completed his residency in internal medicine at New York-Presbyterian/Weill Cornell Medical Center and performed a fellowship in oncology at Johns Hopkins. Dr. Imus is rated as an Experienced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

As an Associate Professor and Director of the Gastrointestinal Program in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins School of Medicine, Dr. Meyer's clinical and research focus is on the treatment of gastrointestinal cancers, including rectal, anal, esophageal, pancreatic, and liver malignancies. He is also leading the effort to establish a liver stereotactic body radiation therapy (SBRT) program within the department. Dr. Meyer has experience with clinical research studies in SBRT, as well as radiation and drug combination therapy for cancer. Make A Gift. Dr. Meyer is rated as an Experienced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Anal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Pancreatic Cancer.

Dr. Ana Kiess's clinical focus is on the treatment of prostate cancer and head and neck cancers with external beam radiotherapy and radiopharmaceutical therapies. Her research concentrates on the integration of new radiopharmaceutical therapies and dosimetry techniques into the clinic. Dr. Kiess received her bachelors of science degree in chemical engineering from the University of Virginia, after which she obtained a doctorate of medicine and a doctorate of philosophy degree in biomedical engineering from Duke University. Following medical school, she matriculated to the resident staff at Memorial Sloan Kettering Cancer Center, receiving extensive oncologic training and research experience. She also completed a postdoctoral research fellowship at Johns Hopkins University in the Department of Radiology. Make A Gift. Dr. Kiess is rated as an Experienced provider by MediFind in the treatment of Follicular Lymphoma. Her top areas of expertise are Prostate Cancer, Laryngeal Cancer, Throat Cancer, Gastrostomy, and Adenoidectomy.

Christian Gocke is a Hematologist in Baltimore, Maryland. Dr. Gocke is rated as an Experienced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Bone Marrow Transplant.

Aaron Rapoport is a Hematologist in Baltimore, Maryland. Dr. Rapoport is rated as a Distinguished provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Carole Miller is an Oncologist in Baltimore, Maryland. Dr. Miller is rated as a Distinguished provider by MediFind in the treatment of Follicular Lymphoma. Her top areas of expertise are Chronic Myelogenous Leukemia (CML), Myeloproliferative Neoplasms (MPN), Philadelphia-Negative Chronic Myeloid Leukemia, and Follicular Lymphoma.

As a member of the Johns Hopkins Kimmel Cancer Center, my group's research is focused on finding novel therapies for the treatment of both acute and chronic graft versus host disease (GVHD). To that end, we are developing new strategies for prophylaxis as well as therapies for this problem. We are exploring the use of drugs such as pentostatin in steroid refractory GVHD. This drug inhibits an enzyme, called ADA, that induces apoptosis (cell death) of lymphocytes, the effector cells in GVHD. Our results using this approach have been quite encouraging. Also, we are exploring other novel approaches such as extracorporeal photopheresis or high-dose cyclophosphamide. We are participating in the NIH Bone Marrow Transplant Clinical Trials Network consortium to find useful therapies for GVHD. We are also members of the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials on Chronic GVHD, and there we are trying to establish rational guidelines for supportive care, trial design, etc. We run an internationally unique GVHD multidisciplinary clinic with many GVHD experts including a nurse practitioner, research nurse and others from fields such as physical medicine and rehabilitation, gastroenterology, ophthalmology, dermatology, pulmonology and more. Dr. Meade is rated as an Experienced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Multiple Myeloma, Childhood Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Panayotis Ledakis is a Hematologist in Baltimore, Maryland. Dr. Ledakis is rated as an Advanced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Appendix Cancer, Desmoplastic Small Round Cell Tumor, Anemia, Colorectal Cancer, and Ureteroscopy.

David Riseberg is a Hematologist in Baltimore, Maryland. Dr. Riseberg is rated as an Advanced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Inflammatory Breast Cancer.

Jean Yared is a Hematologist in Baltimore, Maryland. Dr. Yared is rated as an Advanced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Seung Lee is a Hematologist in Baltimore, Maryland. Dr. Lee is rated as an Advanced provider by MediFind in the treatment of Follicular Lymphoma. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Aspiration, and Splenectomy.